Notice: This company has been marked as potentially delisted and may not be actively trading. Vital Therapies (VTL) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrends VTL vs. GOSS, NBTX, ELDN, GLSI, ATOS, ACRS, GALT, DMAC, SGMT, and IXHLShould you be buying Vital Therapies stock or one of its competitors? The main competitors of Vital Therapies include Gossamer Bio (GOSS), Nanobiotix (NBTX), Eledon Pharmaceuticals (ELDN), Greenwich LifeSciences (GLSI), Atossa Therapeutics (ATOS), Aclaris Therapeutics (ACRS), Galectin Therapeutics (GALT), DiaMedica Therapeutics (DMAC), Sagimet Biosciences (SGMT), and Incannex Healthcare (IXHL). These companies are all part of the "medical" sector. Vital Therapies vs. Gossamer Bio Nanobiotix Eledon Pharmaceuticals Greenwich LifeSciences Atossa Therapeutics Aclaris Therapeutics Galectin Therapeutics DiaMedica Therapeutics Sagimet Biosciences Incannex Healthcare Vital Therapies (NASDAQ:VTL) and Gossamer Bio (NASDAQ:GOSS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends, community ranking and institutional ownership. Which has more risk and volatility, VTL or GOSS? Vital Therapies has a beta of 3.51, indicating that its stock price is 251% more volatile than the S&P 500. Comparatively, Gossamer Bio has a beta of 1.96, indicating that its stock price is 96% more volatile than the S&P 500. Does the media refer more to VTL or GOSS? In the previous week, Gossamer Bio had 14 more articles in the media than Vital Therapies. MarketBeat recorded 15 mentions for Gossamer Bio and 1 mentions for Vital Therapies. Gossamer Bio's average media sentiment score of 0.65 beat Vital Therapies' score of 0.00 indicating that Gossamer Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vital Therapies 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Gossamer Bio 1 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is VTL or GOSS more profitable? Gossamer Bio's return on equity of -127.28% beat Vital Therapies' return on equity.Company Net Margins Return on Equity Return on Assets Vital TherapiesN/A -235.33% -182.35% Gossamer Bio N/A -127.28%-22.12% Do institutionals & insiders have more ownership in VTL or GOSS? 15.5% of Vital Therapies shares are held by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are held by institutional investors. 33.9% of Vital Therapies shares are held by insiders. Comparatively, 5.0% of Gossamer Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Do analysts prefer VTL or GOSS? Gossamer Bio has a consensus price target of $9.20, indicating a potential upside of 1,028.00%. Given Gossamer Bio's stronger consensus rating and higher probable upside, analysts plainly believe Gossamer Bio is more favorable than Vital Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vital Therapies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Gossamer Bio 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable valuation and earnings, VTL or GOSS? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVital TherapiesN/AN/A-$41.47MN/AN/AGossamer BioN/AN/A-$179.82M-$0.32-2.55 Does the MarketBeat Community believe in VTL or GOSS? Vital Therapies received 218 more outperform votes than Gossamer Bio when rated by MarketBeat users. Likewise, 74.40% of users gave Vital Therapies an outperform vote while only 66.23% of users gave Gossamer Bio an outperform vote. CompanyUnderperformOutperformVital TherapiesOutperform Votes36974.40% Underperform Votes12725.60% Gossamer BioOutperform Votes15166.23% Underperform Votes7733.77% SummaryGossamer Bio beats Vital Therapies on 8 of the 13 factors compared between the two stocks. Ad Porter & CompanyWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. Get Vital Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for VTL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VTL vs. The Competition Export to ExcelMetricVital TherapiesPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$48.73M$6.73B$5.12B$8.94BDividend YieldN/A8.07%5.00%4.03%P/E RatioN/A5.4887.1013.96Price / SalesN/A402.901,293.4592.37Price / CashN/A49.2239.0036.42Price / Book3.979.326.425.97Net Income-$41.47M$153.51M$114.18M$224.84M Vital Therapies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VTLVital TherapiesN/A$1.15-6.5%N/A+8.5%$48.73MN/A0.0010GOSSGossamer Bio4.4943 of 5 stars$0.88-0.9%N/A+29.5%$198.83M$95.84M-2.25180Earnings ReportAnalyst ForecastShort Interest ↓Analyst RevisionNews CoverageNBTXNanobiotix2.381 of 5 stars$4.20-2.3%N/A-32.4%$197.96M$36.22M0.00100News CoverageELDNEledon Pharmaceuticals2.7243 of 5 stars$4.83-2.6%N/A+255.8%$191.56MN/A-2.3710Earnings ReportShort Interest ↑News CoverageGap DownGLSIGreenwich LifeSciences2.5803 of 5 stars$14.39+4.2%N/A+29.7%$189.16MN/A-18.223Upcoming EarningsPositive NewsATOSAtossa Therapeutics1.3742 of 5 stars$1.50flatN/A+117.0%$188.64MN/A-7.148Analyst ForecastNews CoverageACRSAclaris Therapeutics2.157 of 5 stars$2.64+7.8%N/A+278.4%$188.36M$31.25M-5.0886Earnings ReportShort Interest ↑Analyst RevisionNews CoverageGALTGalectin Therapeutics2.1157 of 5 stars$3.00+5.6%N/A+48.7%$186.84MN/A-3.809Analyst DowngradeDMACDiaMedica Therapeutics2.2391 of 5 stars$4.30+2.9%N/A+82.1%$183.82MN/A-8.1120News CoverageSGMTSagimet Biosciences2.3363 of 5 stars$5.94-4.0%N/A+170.0%$182.18M$2M0.008Analyst ForecastNews CoverageIXHLIncannex Healthcare1.283 of 5 stars$2.77+14.5%N/A+140.9%$175.84M$10,000.000.003Short Interest ↓Positive News Related Companies and Tools Related Companies GOSS Competitors NBTX Competitors ELDN Competitors GLSI Competitors ATOS Competitors ACRS Competitors GALT Competitors DMAC Competitors SGMT Competitors IXHL Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VTL) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersWhat are you hiding Elon?? (Tesla’s secret 69% dividend)Tesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – ...True Gold Republic | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vital Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vital Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
